First Time Loading...

Ikena Oncology Inc
NASDAQ:IKNA

Watchlist Manager
Ikena Oncology Inc Logo
Ikena Oncology Inc
NASDAQ:IKNA
Watchlist
Price: 1.29 USD -4.44% Market Closed
Updated: Apr 25, 2024

Intrinsic Value

IKNA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Ikena Oncology, Inc. is a clinical stage biotechnology company. [ Read More ]

The intrinsic value of one IKNA stock under the Base Case scenario is 0.91 USD. Compared to the current market price of 1.29 USD, Ikena Oncology Inc is Overvalued by 29%.

Key Points:
IKNA Intrinsic Value
Base Case
0.91 USD
Overvaluation 29%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ikena Oncology Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling IKNA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Ikena Oncology Inc

Provide an overview of the primary business activities
of Ikena Oncology Inc.

What unique competitive advantages
does Ikena Oncology Inc hold over its rivals?

What risks and challenges
does Ikena Oncology Inc face in the near future?

Has there been any significant insider trading activity
in Ikena Oncology Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ikena Oncology Inc.

Provide P/S
for Ikena Oncology Inc.

Provide P/E
for Ikena Oncology Inc.

Provide P/OCF
for Ikena Oncology Inc.

Provide P/FCFE
for Ikena Oncology Inc.

Provide P/B
for Ikena Oncology Inc.

Provide EV/S
for Ikena Oncology Inc.

Provide EV/GP
for Ikena Oncology Inc.

Provide EV/EBITDA
for Ikena Oncology Inc.

Provide EV/EBIT
for Ikena Oncology Inc.

Provide EV/OCF
for Ikena Oncology Inc.

Provide EV/FCFF
for Ikena Oncology Inc.

Provide EV/IC
for Ikena Oncology Inc.

Show me price targets
for Ikena Oncology Inc made by professional analysts.

What are the Revenue projections
for Ikena Oncology Inc?

How accurate were the past Revenue estimates
for Ikena Oncology Inc?

What are the Net Income projections
for Ikena Oncology Inc?

How accurate were the past Net Income estimates
for Ikena Oncology Inc?

What are the EPS projections
for Ikena Oncology Inc?

How accurate were the past EPS estimates
for Ikena Oncology Inc?

What are the EBIT projections
for Ikena Oncology Inc?

How accurate were the past EBIT estimates
for Ikena Oncology Inc?

Compare the revenue forecasts
for Ikena Oncology Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ikena Oncology Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ikena Oncology Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ikena Oncology Inc compared to its peers.

Compare the P/E ratios
of Ikena Oncology Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ikena Oncology Inc with its peers.

Analyze the financial leverage
of Ikena Oncology Inc compared to its main competitors.

Show all profitability ratios
for Ikena Oncology Inc.

Provide ROE
for Ikena Oncology Inc.

Provide ROA
for Ikena Oncology Inc.

Provide ROIC
for Ikena Oncology Inc.

Provide ROCE
for Ikena Oncology Inc.

Provide Gross Margin
for Ikena Oncology Inc.

Provide Operating Margin
for Ikena Oncology Inc.

Provide Net Margin
for Ikena Oncology Inc.

Provide FCF Margin
for Ikena Oncology Inc.

Show all solvency ratios
for Ikena Oncology Inc.

Provide D/E Ratio
for Ikena Oncology Inc.

Provide D/A Ratio
for Ikena Oncology Inc.

Provide Interest Coverage Ratio
for Ikena Oncology Inc.

Provide Altman Z-Score Ratio
for Ikena Oncology Inc.

Provide Quick Ratio
for Ikena Oncology Inc.

Provide Current Ratio
for Ikena Oncology Inc.

Provide Cash Ratio
for Ikena Oncology Inc.

What is the historical Revenue growth
over the last 5 years for Ikena Oncology Inc?

What is the historical Net Income growth
over the last 5 years for Ikena Oncology Inc?

What is the current Free Cash Flow
of Ikena Oncology Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ikena Oncology Inc.

Financials

Balance Sheet Decomposition
Ikena Oncology Inc

Current Assets 178.7m
Cash & Short-Term Investments 175.5m
Other Current Assets 3.2m
Non-Current Assets 13.4m
PP&E 8m
Other Non-Current Assets 5.4m
Current Liabilities 14.2m
Accounts Payable 2.1m
Accrued Liabilities 12.1m
Other Current Liabilities 85k
Non-Current Liabilities 8.1m
Other Non-Current Liabilities 8.1m
Efficiency

Earnings Waterfall
Ikena Oncology Inc

Revenue
9.2m USD
Operating Expenses
-84.6m USD
Operating Income
-75.4m USD
Other Expenses
7.3m USD
Net Income
-68.2m USD

Free Cash Flow Analysis
Ikena Oncology Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

IKNA Profitability Score
Profitability Due Diligence

Ikena Oncology Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

Positive Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
14/100
Profitability
Score

Ikena Oncology Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.

IKNA Solvency Score
Solvency Due Diligence

Ikena Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Ikena Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

IKNA Price Targets Summary
Ikena Oncology Inc

Wall Street analysts forecast IKNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IKNA is 8.33 USD .

Lowest
Price Target
Not Available
Average
Price Target
8.33 USD
546% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

IKNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

IKNA Price
Ikena Oncology Inc

1M 1M
-10%
6M 6M
-69%
1Y 1Y
-74%
3Y 3Y
-94%
5Y 5Y
-92%
10Y 10Y
-92%
Annual Price Range
1.29
52w Low
1.24
52w High
7.31
Price Metrics
Average Annual Return -47.38%
Standard Deviation of Annual Returns 47.56%
Max Drawdown -96%
Shares Statistics
Market Capitalization 62.3m USD
Shares Outstanding 48 260 000
Percentage of Shares Shorted 3.35%

IKNA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Ikena Oncology Inc Logo
Ikena Oncology Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

62.3m USD

Dividend Yield

0%

Description

Ikena Oncology, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. The company intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The firm is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. The company also has early stage discovery programs in targeted oncology in the RAS pathway.

Contact

MASSACHUSETTS
Boston
50 Northern Ave.
+18573438292.0
https://www.ikenaoncology.com

IPO

2021-03-26

Employees

67

Officers

President, CEO & Director
Dr. Mark Manfredi Ph.D.
CFO & Head of Corporate Development
Dr. Jotin Marango M.D., Ph.D.
Senior Vice President of Finance & Operations
Mr. Bob Lally
VP & Deputy General Counsel
Ms. Srividya Subramanian Esq., Ph.D.
Head of Human Resources
Ms. Samantha Vuksanic
Chief Development Officer
Mr. Jeffrey Ecsedy Ph.D.
Show More
VP & Head of Quality
Mr. Navin Parwani M.S.
Senior Vice President of Clinical Development Operations
Mr. David Damphousse M.S.
Chief Medical Officer
Dr. Caroline Germa M.D.
Senior Vice President of Technical Operations
Mr. Valdas Jurkauskas Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one IKNA stock?

The intrinsic value of one IKNA stock under the Base Case scenario is 0.91 USD.

Is IKNA stock undervalued or overvalued?

Compared to the current market price of 1.29 USD, Ikena Oncology Inc is Overvalued by 29%.